Department of Cell and Molecular Biology, Dr. Rema Mohan High-Throughput Screening (HTS) Lab, Madras Diabetes Research Foundation and Dr. Mohan's Diabetes Specialties Centre, 4, Conran Smith Road, Gopalapuram, Chennai, 600 086, India.
National Dairy Research Institute (NDRI), Karnal, Haryana, 132001, India.
Eur J Nutr. 2018 Feb;57(1):279-295. doi: 10.1007/s00394-016-1317-7. Epub 2016 Oct 18.
PURPOSE: Diabetes and obesity are characterized by glucose intolerance, fat deposition, inflammation, and dyslipidemia. Recent reports postulated that distinct gut microbiota alterations were observed in obese/diabetic subjects and modulating gut microbiota beneficially through specific probiotics could be a potential therapeutic option for type 2 diabetes/obesity. Therefore, we attempted to study the efficacy of probiotics of Indian gut origin (Lactobacillus plantarum MTCC5690 and Lactobacillus fermentum MTCC5689) along with a positive control, Lactobacillus rhamnosus (LGG) on glucose/lipid homeostasis in high-fat-diet-induced diabetic animal model. METHODS: C57BL/6J male mice were divided into seven groups (n = 6 per group) comprising feeding on: (1) Normal Pellet Diet (NPD), (2) High-Fat Diet (HFD), (3) HFD with LGG, (4) HFD with MTCC5690, (5) HFD with MTCC5689, (6) HFD with metformin, and 7) HFD with vildagliptin for a period of 6 months. Biochemical markers, glucose tolerance, insulin resistance, and GLP-1 and LPS levels were assessed by standard protocols. Gut integrity was measured by intestinal permeability test. Transcriptional levels of tight junction proteins (TJPs) were probed in small intestinal tissues while inflammatory signals and other pathway specific genes were profiled in liver, visceral adipose tissue, and skeletal muscle. RESULTS: Mice fed with HFD became insulin resistant, glucose intolerant, hyperglycemic, and dyslipidemic. Diabetic mice were characterized to exhibit decreased levels of GLP-1, increased gut permeability, increased circulatory levels of LPS, decrease in the gene expression patterns of intestinal tight junction markers (occludin and ZO-1), and increased proinflammatory gene markers (TNFα and IL6) in visceral fat along with decreased mRNA expression of FIAF and adiponectin. Diabetic mice also exhibited increased mRNA expression of ER stress markers in skeletal muscle. In addition, liver from HFD-fed diabetic mice showed increased gene expressions of proinflammation, lipogenesis, and gluconeogenesis. Probiotic interventions (most prominently the MTCC5689) resisted insulin resistance and development of diabetes in mice under HFD feeding and beneficially modulated all the biochemical and molecular alterations in a mechanistic way in several tissues. The metabolic benefits offered by the probiotics were also more or less similar to that of standard drugs such as metformin and vildagliptin. CONCLUSION: Native probiotic strains MTCC 5690 and MTCC 5689 appear to have potential against insulin resistance and type 2 diabetes with mechanistic, multiple tissue-specific mode of actions.
目的:糖尿病和肥胖症的特征是葡萄糖耐量降低、脂肪沉积、炎症和血脂异常。最近的报告假设,肥胖/糖尿病患者的肠道微生物群发生了明显改变,通过特定的益生菌来有益地调节肠道微生物群可能是 2 型糖尿病/肥胖症的一种潜在治疗选择。因此,我们试图研究印度肠道来源的益生菌(植物乳杆菌 MTCC5690 和发酵乳杆菌 MTCC5689)以及阳性对照鼠李糖乳杆菌(LGG)对高脂肪饮食诱导的糖尿病动物模型中葡萄糖/脂质稳态的疗效。
方法:将 C57BL/6J 雄性小鼠分为七组(每组 6 只),分别喂食:(1)普通颗粒饮食(NPD)、(2)高脂肪饮食(HFD)、(3)HFD 加 LGG、(4)HFD 加 MTCC5690、(5)HFD 加 MTCC5689、(6)HFD 加二甲双胍和 7)HFD 加维格列汀,持续 6 个月。通过标准方案评估生化标志物、葡萄糖耐量、胰岛素抵抗以及 GLP-1 和 LPS 水平。通过肠道通透性试验测量肠道完整性。在小肠组织中检测紧密连接蛋白(TJPs)的转录水平,同时在肝脏、内脏脂肪组织和骨骼肌中分析炎症信号和其他通路特异性基因。
结果:喂食 HFD 的小鼠表现出胰岛素抵抗、葡萄糖不耐受、高血糖和血脂异常。糖尿病小鼠的特征是 GLP-1 水平降低、肠道通透性增加、循环 LPS 水平升高、肠紧密连接标志物(occludin 和 ZO-1)的基因表达模式减少以及内脏脂肪中促炎基因标志物(TNFα 和 IL6)增加,同时骨骼肌中 FIAF 和脂联素的 mRNA 表达减少。HFD 喂养的糖尿病小鼠的骨骼肌还表现出 ER 应激标志物的 mRNA 表达增加。此外,HFD 喂养的糖尿病小鼠的肝脏表现出促炎、脂肪生成和糖异生基因表达增加。益生菌干预(最突出的是 MTCC5689)抵抗了高脂肪饮食喂养小鼠的胰岛素抵抗和糖尿病的发展,并以一种机制的方式有益地调节了几种组织中的所有生化和分子改变。益生菌提供的代谢益处与二甲双胍和维格列汀等标准药物相似。
结论:本土益生菌株 MTCC5690 和 MTCC5689 似乎具有针对胰岛素抵抗和 2 型糖尿病的潜力,具有机制上的、多种组织特异性的作用模式。
J Nutr Biochem. 2017-12
Benef Microbes. 2010-6
Int J Mol Sci. 2025-8-19
Probiotics Antimicrob Proteins. 2025-5-7
Front Microbiol. 2025-3-14
Diabetes Obes Metab. 2025-4
Pharmaceuticals (Basel). 2025-1-6
Microorganisms. 2024-8-24
Diabetol Metab Syndr. 2015-9-12